SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending due to its highly anticipated earnings report, with community discussion polarized between expectations of surging AI revenue and concerns over high valuation and potential post-earnings sell-offs mirroring other recent tech reports.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging as a substantial patent settlement removes a major legal overhang, while the FDA's reversal to review its flu vaccine application is driving bullish sentiment and sparking community talk of a massive short squeeze, with attention now turning to its promising oncology pipeline.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is actively trending following its latest earnings report, which, despite an earnings and revenue beat with raised guidance, saw the stock decline due to investor concerns over the lack of fiscal 2027 outlook and broader AI disruption fears within the cybersecurity sector. The community is sharply divided, debating if the sell-off is an overreaction or if the stock will continue its historical underperformance.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending due to escalating geopolitical tensions, which are spotlighting its advanced tactical drone systems, especially the Black Widow, amidst increasing defense sector demand and US Army initiatives. Community discussions center on the anticipation of significant contract awards and a potential short squeeze.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending amidst fervent buyout speculation, fueled by recent volume spikes and rumors of potential acquisition by suitors such as Jazz Pharmaceuticals or Ipsen. The community is actively debating a potential takeover, with many believing the company's strong oncology pipeline, including OJEMDA and the Mersana acquisition, and current valuation make it an attractive target in an active M&A market.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini (GEMI) is sparking significant community discussion after securing a CFTC Designated Contract Market license and launching its prediction market, leading to speculation about a short squeeze and its potential to ride a Bitcoin rally, even as past underperformance raises investor skepticism.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending ahead of its Q4 earnings report, with community sentiment largely negative due to sustained underperformance and price declines, even as some investors highlight its low valuation, substantial cash reserves, and strategic competitive advantages within the Chinese e-commerce sector.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF is highly volatile amid geopolitical concerns that triggered market circuit breakers; however, robust underlying demand for AI-driven memory chips from major holdings like Samsung and SK Hynix is fueling a strong rebound, leading community discussion on whether initial market fear was overblown.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending after securing a $2.4 billion contract to build a 1.2-gigawatt natural gas plant for Applied Digital's AI data centers, a deal widely regarded as transformational given its magnitude relative to the company's market capitalization. The community is actively discussing BW's strong position to rapidly deliver critical power solutions for the booming AI infrastructure, with potential for further substantial projects.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending after securing crucial EPA, UK, and EU regulatory clearances, which unlock commercial sales of its pure graphene across major global markets. This development, coupled with an oversubscribed capital raise and upcoming facility ramp-ups, is fueling community excitement for the company's revolutionary material and its vast, multi-sector potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised shares of Novavax from a "sell" rating to a "hold" rating in a research note on Saturday...

Novavax (NASDAQ:NVAX) Trading Down 9.8% - Here's What Happened

Novavax (NASDAQ:NVAX) Stock Price Down 9.8% - Time to Sell...

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.

Company News for Feb 27, 2026

Companies In The Article Are:NVAX,SJM,SHAK,ACMR

<ul class="summary-bullets"><li>The company highlighted Sanofi’s flu-COVID combination shot as a key long-term driver.</li><li>Q4 revenue rose 67% to $147 million, while full-year revenue climbed 65% to $1.12 billion.</li><li>Internal pipeline programs targeting C. difficile, shingles and RSV combinations are advancing, with at least one candidate potentially entering clinical trials by 2027.</li></ul>Shares of Novavax, Inc. (NVAX) hit a more than one-year high on Thursday as investors turned their focus to future growth beyond standalone COVID vaccines, led by its partnership strategy and Sanofi’s flu-COVID combination shot.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped over 17% on Thursday, but slipped 1.3% in extended trading.<h2 class="st-heading-2">Novavax Bets On Combo Vaccines</h2>During its fourth-quarter (Q4) earnings call, the biotech company said it has moved away from its earlier structure centered on standalone COVID vaccine commercialization and is now focused on expanding its pipeline through partnership-led growth.“We have evolved Novavax from a vertically integrated global commercial organization with a singular focus on COVID to a company that is focused on driving both near and long-term value with our proven technology platform via partnering and R&amp;D,” CEO John Jacobs said on the call.A key pillar of the strategy is Sanofi’s development of combination vaccines that pair its flu products with Novavax’s COVID-19 vaccine, Nuvaxovid. The company noted that it would be eligible for a $125 million milestone upon the start of the Phase 3 study for the program.Novavax also pointed to positive early-stage data shared by Sanofi, and added that market research suggests a large share of people who already receive both vaccines would consider switching to a single combination shot.Looking ahead, Novavax expects the 2026-2027 season to mark the first full commercial cycle in which Sanofi markets Nuvaxovid globally. “So yes, the upcoming season looks very promising,” said Elaine O'Hara, chief strategy officer.<h2 class="st-heading-2">Pfizer Matrix Deal Expands Pipeline</h2>In January, the company signed a licensing agreement with Pfizer allowing the use of Matrix-M in two vaccine programs, including one already identified. The company noted that additional material transfer agreements were signed this month, including one with an oncology-focused partner.“We're seeing that once vaccine-focused companies experiment with our adjuvant, they often come back to us to explore more broadly,” the company said. “Our Matrix technology is a cornerstone of our partnering model.”&nbsp;Additionally, early-stage internal vaccine programs targeting C. difficile, shingles and RSV combinations are advancing, with at least one candidate potentially entering clinical testing as early as 2027.The company said that the broader aim is to build a diversified set of recurring revenue streams tied to partnerships and future commercial programs.<h2 class="st-heading-2">NVAX Q4 Review</h2>Novavax reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-swings-to-profit-in-q4-nuvaxovid-revenue/cZTGfprRIbH">Q4 revenue</a> of $147 million, marking a 67% year-on-year increase, and also beating consensus estimates of $90.26 million. Earnings per share (EPS) came in at $0.11, surpassing analyst expectations of $0.55, according to Fiscal AI data.Full-year revenue rose 65% to $1.12 billion, driven largely by $625 million in Nuvaxovid-related sales tied to settlements of earlier advance purchase agreements.Quarterly product sales stood at $39 million, while full-year product sales climbed to $685 million. Revenue recognized under the Sanofi partnership, including milestone and royalty payments, totaled $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestone payments from the Sanofi collaboration in 2025.&nbsp;Looking ahead, Novavax expects adjusted total revenue of $230 million to $270 million in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for NVAX was ‘extremely bullish’ amid a 580% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_d2beb88a95.webp" alt="nvax ss.png" width="970" height="144"><figcaption>NVAX sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BigCheeze2014/message/646069243">said</a>, “Institutional and Retail FOMO buying will start the squeeze.”<stembedurl>https://stocktwits.com/BigCheeze2014/message/646069243</stembedurl>Another user <a href="https://stocktwits.com/knndy/message/646066793">said</a>, “Friday should see continuing strong Buying pressure coupled with urgent short covering as well.”<stembedurl>https://stocktwits.com/knndy/message/646066793</stembedurl>NVAX stock has jumped 67% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Ampoules containing the new Corona vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center. Photo: Matthias Bein/dpa (Photo by Matthias Bein/picture alliance via Getty Images)

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver?

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Equity

Novavax Q4 Earnings Call Highlights

Novavax (NASDAQ:NVAX) executives told investors the company made significant progress in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller...

Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS

Novavax (NASDAQ:NVAX - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus...

Power Hour Surge: Quantum Breakouts, Biotech Visibility, and Crypto Strategy Running into the Close

As Wall Street heads into the final hour of trading, momentum is clustering around quantum computing, next-gen biomaterials, vaccine platforms, and digital asset strategy plays. Today’s stock market tape is being defined by revenue beats, national infrastructure deployments, major licensing deals, and one headline-grabbing magazine cover that has small-cap traders leaning forward into the bell. $KBLB, $AEHL, $NVAX, $RXT, $BFLY, $INOQ

Novavax to Participate in Upcoming Investor Conferences

Novavax to Participate in Upcoming Investor Conferences Novavax to Participate in Upcoming Investor Conferences PR Newswire GAITHERSBURG, Md., Feb. 26, 2026 GAITHERSBURG, Md., Feb. 26, 2026...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Novavax Inc

Shareholders are increasingly vocal about perceived mismanagement and lack of deals from CEO John Jacobs, holding him accountable for the stock's poor performance.

Many traders are frustrated by persistent short seller activity, calling for a short squeeze amidst accusations of stock manipulation.

Serum Institute of India gained CDSCO approval for Phase 3 trials of its COVID-Flu combination vaccine utilizing Novavax's Matrix-M platform.

Traders are actively comparing Novavax's lagging performance to Moderna's recent stock rally, fueled by a major patent settlement.

Traders closely monitor key resistance levels, particularly the $10 mark, hoping for a sustained breakout into double-digit prices.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.23	--	--	N/A
Q4 '25	-$0.48	$0.11	122.69%	BEAT
Q3 '25	-$1.20	-$1.25	-4.49%	MISSED
Q2 '25	-$0.04	$0.62	1849.19%	BEAT
Q1 '25	-$0.42	$2.93	792.13%	BEAT

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest NVAX News

NVAXNovavax Inc